Background Romidepsin is a structurally unique, potent, bicyclic class 1 selective histone
deacetylase inhibitor approved by the US Food and Drug Administration for the treatment of …

Purpose Romidepsin is a structurally unique, potent class 1 selective histone deacetylase
inhibitor. The primary objective of this international, pivotal, single-arm, phase II trial was to …

Background Achievement of durable responses in patients with relapsed/refractory
peripheral T cell lymphoma (PTCL) is challenging with current therapies, and there are few …

Peripheral T-cell lymphomas (PTCLs) are a rare, heterogeneous group of T-cell–or natural
killer cell–derived non-Hodgkin lymphomas. The majority of patients with PTCL experience …

This phase I/II multicenter study evaluated romidepsin treatment in Japanese patients with
relapsed/refractory peripheral T-cell lymphoma (PTCL) or cutaneous T-cell lymphoma …

Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of non-Hodgkin lymphomas
associated with poor prognosis in most subtypes. Diagnosis of this rare disease by expert …

Background Romidepsin is a histone deacetylase inhibitor approved in the USA for patients
with recurrent or refractory peripheral T-cell lymphoma and has shown activity in this setting …

Romidepsin (depsipeptide or FK228) is a histone deacetylase inhibitor, one of a new class
of agents active in T-cell lymphoma. A phase 2 trial was conducted in cutaneous (CTCL) and …

The most common subtypes of primary cutaneous T-cell lymphoma (CTCL) are mycosis
fungoides and Sézary syndrome. Clinical manifestations and prognosis in CTCL are highly …

PURPOSE Romidepsin, a histone deacetylase inhibitor, has demonstrated activity in
relapsed or refractory peripheral T-cell lymphoma (PTCL) as a single agent …